Cantor Fitzgerald Decreases Earnings Estimates for Ardelyx

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for Ardelyx in a note issued to investors on Wednesday, May 7th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biopharmaceutical company will earn ($0.44) per share for the year, down from their previous estimate of ($0.13). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Several other equities research analysts also recently commented on ARDX. Scotiabank assumed coverage on shares of Ardelyx in a research report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. LADENBURG THALM/SH SH reissued a “buy” rating and set a $11.00 price objective on shares of Ardelyx in a report on Friday, March 7th. StockNews.com lowered Ardelyx from a “hold” rating to a “sell” rating in a report on Monday, May 5th. HC Wainwright reiterated a “neutral” rating and set a $5.50 price target on shares of Ardelyx in a report on Friday, February 21st. Finally, Raymond James lowered Ardelyx from a “strong-buy” rating to an “outperform” rating and set a $11.00 price target for the company. in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.39.

Ardelyx Stock Performance

ARDX opened at $3.62 on Friday. Ardelyx has a 1-year low of $3.50 and a 1-year high of $8.14. The company has a market cap of $866.10 million, a price-to-earnings ratio of -22.63 and a beta of 0.76. The company’s fifty day moving average price is $4.85 and its two-hundred day moving average price is $5.18. The company has a current ratio of 4.58, a quick ratio of 4.31 and a debt-to-equity ratio of 0.87.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%. The firm had revenue of $74.11 million for the quarter, compared to analyst estimates of $79.40 million. During the same period in the previous year, the company earned ($0.11) earnings per share. Ardelyx’s revenue for the quarter was up 61.1% compared to the same quarter last year.

Insiders Place Their Bets

In other Ardelyx news, insider Laura A. Williams sold 4,941 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $5.62, for a total value of $27,768.42. Following the transaction, the insider now directly owns 303,804 shares in the company, valued at $1,707,378.48. The trade was a 1.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Raab sold 22,964 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $5.62, for a total transaction of $129,057.68. Following the transaction, the chief executive officer now directly owns 1,085,755 shares of the company’s stock, valued at $6,101,943.10. This represents a 2.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 158,076 shares of company stock valued at $777,555. Insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ARDX. GF Fund Management CO. LTD. purchased a new stake in Ardelyx in the 4th quarter worth about $25,000. Newbridge Financial Services Group Inc. purchased a new stake in Ardelyx during the fourth quarter valued at about $35,000. SBI Securities Co. Ltd. bought a new position in Ardelyx during the fourth quarter worth about $41,000. Cyndeo Wealth Partners LLC purchased a new position in shares of Ardelyx in the first quarter worth about $49,000. Finally, Quarry LP bought a new stake in shares of Ardelyx in the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.